ethoheptazine ethoheptazine ethoheptazine (trade name zactane) is an opioid analgesic from the phenazepane family. it was invented in the 1950s and is a ring expanded analogue of pethidine. ethoheptazineclinical datatrade namesequagesicother nameszactaneroutes ofadministrationoralatc codenonelegal statuslegal status us: schedule iv (some preparations) identifiers iupac name ethyl 1-methyl-4-phenylazepane-4-carboxylate cas number77-15-6 npubchem cid6469drugbankdb08988 nchemspider6225 yunii3a4g3a848uchemblchembl170797 ncomptox dashboard (epa)dtxsid7023017 echa infocard100.000.917 chemical and physical dataformulac16h23no2molar mass261.365 g·mol−13d model (jsmol)interactive image smiles o=c(occ)c2(c1ccccc1)ccn(c)ccc2 inchi inchi=1s/c16h23no2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9h,3,7,10-13h2,1-2h3 ykey:wgjhhmkqbwsqiy-uhfffaoysa-n y ny (what is this?) (verify) ethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea. it was sold by itself as zactane, and is still available as a combination product with acetylsalicylic acid and meprobamate as equagesic, which is used for the treatment of conditions where both pain and anxiety are present. it was also investigated for use as an antitussive. it is no longer prescribed, as it is no longer fda approved, and not available for united states' pharmacy processing. revocation of fda approved medications status stems from a combination of efficacy vs. toxicity, and the more-varied and historically safer benzodiazepines class. only reversal of the fda's decision, allows removing the drug from the csd. ethoheptazine is not listed as a controlled substance under the controlled substances act, 1970 in the united states. the controlled status (schedule iv) of equagesic was due to the meprobamate content. regulation elsewhere varies.